Expedeon completes asset sale, changes name

Country

Germany

Expedeon AG has completed the sale of its proteomics and immunology business to Abcam Plc of the UK for €120 million, leading to a repositioning of the company as a provider of genomics services. Based in Heidelberg, Germany, Expedeon will in future focus on manufacturing DNA for use in gene therapies and gene-based vaccines. It will henceforth go by the name 4basebio AG and will continue to be listed on the Frankfurt Stock Exchange.